These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry. Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817 [TBL] [Abstract][Full Text] [Related]
6. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Yang ZZ; Grote DM; Ziesmer SC; Xiu B; Novak AJ; Ansell SM Blood Cancer J; 2015 Feb; 5(2):e281. PubMed ID: 25700246 [TBL] [Abstract][Full Text] [Related]
7. PD-1 Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814 [TBL] [Abstract][Full Text] [Related]
8. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer. Heiduk M; Klimova A; Reiche C; Digomann D; Beer C; Aust DE; Distler M; Weitz J; Seifert AM; Seifert L Clin Cancer Res; 2023 Jul; 29(14):2638-2650. PubMed ID: 37140899 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral TIGIT Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209 [TBL] [Abstract][Full Text] [Related]
11. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Minnie SA; Kuns RD; Gartlan KH; Zhang P; Wilkinson AN; Samson L; Guillerey C; Engwerda C; MacDonald KPA; Smyth MJ; Markey KA; Vuckovic S; Hill GR Blood; 2018 Oct; 132(16):1675-1688. PubMed ID: 30154111 [TBL] [Abstract][Full Text] [Related]
12. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma. Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897 [TBL] [Abstract][Full Text] [Related]
13. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. Simon S; Voillet V; Vignard V; Wu Z; Dabrowski C; Jouand N; Beauvais T; Khammari A; Braudeau C; Josien R; Adotevi O; Laheurte C; Aubin F; Nardin C; Rulli S; Gottardo R; Ramchurren N; Cheever M; Fling SP; Church CD; Nghiem P; Dreno B; Riddell SR; Labarriere N J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188038 [TBL] [Abstract][Full Text] [Related]
14. Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 Yang ZZ; Kim HJ; Villasboas JC; Price-Troska T; Jalali S; Wu H; Luchtel RA; Polley MC; Novak AJ; Ansell SM Cell Rep; 2019 Feb; 26(8):2178-2193.e3. PubMed ID: 30784598 [TBL] [Abstract][Full Text] [Related]
15. TIGIT presents earlier expression dynamic than PD-1 in activated CD8 Hu F; Wang W; Fang C; Bai C Exp Cell Res; 2020 Nov; 396(1):112260. PubMed ID: 32890458 [TBL] [Abstract][Full Text] [Related]
16. The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential. Watanabe T Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069564 [TBL] [Abstract][Full Text] [Related]
17. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972 [TBL] [Abstract][Full Text] [Related]
18. TOX-expressing terminally exhausted tumor-infiltrating CD8 Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194 [TBL] [Abstract][Full Text] [Related]
19. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia. Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919 [TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers. Hosseinkhani N; Shadbad MA; Asghari Jafarabadi M; Karim Ahangar N; Asadzadeh Z; Mohammadi SM; Lotfinejad P; Alizadeh N; Brunetti O; Fasano R; Silvestris N; Baradaran B Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]